Redbiotec develops prophylactic vaccines, with a strong focus on HCMV (human cytomegalovirus).
Redbiotec provides reVLPs as a display platform for multispanning membrane proteins like GPCRs (G Protein-coupled receptors) and ion channels.
Swiss Economic Forum labels Redbiotec as High Potential SME
Schlieren, 18 February 2013
We are pleased to announce that Redbiotec has been labeled "High Potential SME" by the Swiss Economic Forum (SEF) through a certified process. This is a further proof for Redbiotec's high value business.
New agreement with Roche
Schlieren, 07 December 2012
Redbiotec AG has signed a new agreement with Roche Diagnostics GmbH, Germany, under which it will apply its proprietary technology platform rePAX® to produce VLPs. Roche intends to use the VLPs in an antibody discovery program in an undisclosed area.